STUDY SHOWS PFIZER VACCINE IS MODERATELY EFFECTIVE AGAINST OMICRON FOR CHILDREN 5-15
ROCKVILLE, Md., March 11, 2022 /PRNewswire/ -- A new study by the Centers for Disease Control and Prevention (CDC) and Abt Associates shows that the Pfizer-BioNTech COVID-19 vaccine is moderately effective against the Omicron variant for children ages 5-15.
- ROCKVILLE, Md., March 11, 2022 /PRNewswire/ -- A new study by the Centers for Disease Control and Prevention (CDC) and Abt Associates shows that the Pfizer-BioNTech COVID-19 vaccine is moderately effective against the Omicron variant for children ages 5-15.
- It reduced the risk of infection by 31% for children 5-11 and by 59% for children 12-15.
- The Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT) study, which used real-world data, found that the vaccine was moderately effective against Delta and Omicron infection and that vaccinated children spent less time sick in bed than unvaccinated children with an Omicron infection.
- Researchers cautioned that the vaccinated children wore masks more often at school than the unvaccinated children, which could have affected the results.